Mereo BioPharma (MREO) Assets (2017 - 2026)

Mereo BioPharma (MREO) has reported Assets for 8 consecutive years, with $34.7 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Assets fell 44.57% year-over-year to $34.7 million in Q2 2026; TTM through Jun 2026 was $34.7 million, a 44.57% decrease from a year earlier, with the FY2025 full-year figure at $45.9 million, down 39.89% from the prior year.
• Assets was $34.7 million for Q2 2026 at Mereo BioPharma, down from $40.6 million in the prior quarter.
• Over five years, Assets peaked at $96.1 million in Q2 2024 and troughed at $34.7 million in Q2 2026.
• A 4-year average of $62.7 million and a median of $62.6 million in 2025 frame the typical range for Assets.
• Across the five-year window, Assets climbed 22.14% in 2025 and tumbled 44.57% in 2026, its largest moves.
• Over 4 years, Assets stood at $66.5 million in 2023, then rose by 14.87% to $76.4 million in 2024, then sank by 39.89% to $45.9 million in 2025, then declined by 24.4% to $34.7 million in 2026.
• The last three Assets figures came in at $34.7 million (Q2 2026), $40.6 million (Q1 2026), and $45.9 million (Q4 2025), per Business Quant data.